Clinical trials
Terminated Autoimmune Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 37 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 4 |
| Eli Lilly and Company | 3 |
| Immunovant Sciences GmbH | 3 |
| Kyverna Therapeutics | 2 |
| Massachusetts General Hospital | 2 |
| Novartis Pharmaceuticals | 2 |
| Alliance Foundation Trials, LLC. | 1 |
| Amgen | 1 |
| Atara Biotherapeutics | 1 |
| Brigham and Women's Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Autoimmune Diseases | 37 |
| Lupus Erythematosus, Systemic | 9 |
| Arthritis, Rheumatoid | 7 |
| Diabetes Mellitus, Type 1 | 5 |
| Immune System Diseases | 5 |
| Connective Tissue Diseases | 4 |
| Multiple Sclerosis | 4 |
| Rheumatic Diseases | 4 |
| Scleroderma, Systemic | 4 |
| Arthritis | 3 |
Trials
Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.